Page 12 - Associations Code News Today

"registration date" -, either by entry in the register of registered shares or by entry in the accounts of an approved account keeper or central securities depository, regardless of the... | April 14, 2022

A concise Q&A guide exploring the legal framework for corporate reorganisations in Belgium, including types of transaction, reorganisation structure, laws and regulation and more.

LUXEMBOURG, Feb. 24, 2022 /PRNewswire/ -- THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIED OR MAY HAVE QUALIFIED AS INSIDE INFORMATION FOR THE PURPOSES OF (I)

LUXEMBOURG, Feb. 24, 2022 /PRNewswire/ -- THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIED OR MAY HAVE QUALIFIED AS INSIDE ...

This article reviews the essential regulatory considerations surrounding medicines and medical devices in United Kingdom, including clinical trials and marketing authorisations.

A quick look at some of the key considerations for foreign suppliers seeking to establish direct distribution structures in Belgium.

REGULATED INFORMATION NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES,...

Sectiunea Dosare Juridice >> Opinia specialiștilor Stoica & Asociaţii din Hotnews.ro: stiri de ultima ora, articole, opinii, analize din Dosare Juridice >> Opinia specialiștilor Stoica & Asociaţii

Press release content from Globe Newswire. The AP news staff was not involved in its creation. MDxHealth Announces its Ordinary and Extraordinary General Shareholders’ Meetings MDxHealth (R)April 27, 2021 GMT NEWS RELEASE – REGULATED INFORMATION 27 April 2021, 7:00 a.m. CET IRVINE, CA, and HERSTAL, BELGIUM – 27 April 2021 – MDxHealth SA (Euronext Brussels: MDXH) (the “Company” or “MDxHealth”) a commercial-stage innovative molecular diagnostics company, today invites the holders ...

Sequana Medical NV: Transparency Notifications from Shareholders Ghent, BELGIUM - 23 February 2021 - Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company" or " Sequana Medical"), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces today in accordance with Article 14 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated ma...